NTC
VKTX icon

NF Trinity Capital’s Viking Therapeutics VKTX Stock Holding History

NF Trinity Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.39M Hold
140,000
– – 0.22% 37
2018
Q4 		$1.07M Buy
+140,000
New +$1.67M 0.17% 44

Other funds holding VKTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

NF Trinity Capital's VKTX Position: Q1 2019 in Review

NF Trinity Capital held its Viking Therapeutics (VKTX) position steady in Q1 2019 at 140,000 shares worth $1.39M. The position accounts for 0.22% of the portfolio, ranked #37.

NF Trinity Capital first reported a position in VKTX in Q4 2018 and has held it in 2 quarters since. 164 funds tracked by Wall St. Rank hold VKTX as of Q1 2019.

  • NF Trinity Capital held 140,000 shares of Viking Therapeutics worth $1.39M as of Q1 2019.
  • NF Trinity Capital left its Viking Therapeutics share count unchanged in Q1 2019.
  • Viking Therapeutics made up 0.22% of NF Trinity Capital's portfolio in Q1 2019, its #37 holding.
  • NF Trinity Capital first reported a position in Viking Therapeutics in Q4 2018 and has held it in 2 quarters since.
  • 164 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2019.

Based on NF Trinity Capital's 13F filing for Q1 2019, filed 10 May 2019.